Relevant bibliographies by topics / Transdermal Drug Delivery System

Academic literature on the topic 'Transdermal Drug Delivery System'

Author: Grafiati
Published: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Transdermal Drug Delivery System.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Transdermal Drug Delivery System"

1

K Purushotham and K Anie Vijetha. "A review on transdermal drug delivery system." GSC Biological and Pharmaceutical Sciences 22, no. 2 (February 28, 2023): 245–55. http://dx.doi.org/10.30574/gscbps.2023.22.2.0053.

Full text
Abstract:
In order to produce systemic effects, transdermal drug delivery systems (TDDS), commonly referred to as "patches," are dosage forms that are intended to spread a therapeutically active amount of medicine across the skin of a patient. Drugs that are applied topically are delivered using transdermal drug delivery devices. These are pharmaceutical preparations of varying sizes, containing one or more active ingredients, intended to be applied to the unbroken skin in order to deliver the active ingredient after passing through the skin barriers, and these avoid first pass metabolism. Today about 74% of drugs are taken orally and are not found effective as desired. To improve efficacy transdermal drug delivery system was emerged. In TDDS the drug easily penetrates into the skin and easily reaches the target site. To get around the problems with medicine delivery via oral route, transdermal drug delivery systems were developed. These systems have been utilized as secure and reliable drug delivery systems since 1981.
APA, Harvard, Vancouver, ISO, and other styles
2

Sadab, Sadab, Sarad Sahu, Shubham Patel, Rubeena Khan, Basant Khare, Bhupendra Singh Thakur, Anushree Jain, and Prateek Kumar Jain. "A Comprehensive Review: Transdermal Drug Delivery System: A Tool For Novel Drug Delivery System." Asian Journal of Dental and Health Sciences 2, no. 4 (December 15, 2022): 40–47. http://dx.doi.org/10.22270/ajdhs.v2i4.24.

Full text
Abstract:
In the recent decade, skin delivery (topical and transdermal) has gained an unprecedented popularity, especially due to increased incidences of chronic skin diseases, demand for targeted and patient compliant delivery and interest in life cycle management strategies among pharmaceutical companies. Transdermal drug delivery system was presented to overcome the difficulties of drug delivery especially oral route. Transdermal drug delivery refers to a means of delivering drugs through the surface of the skin for local or systemic treatment. The drug functions after absorption through the skin into the systemic circulation via capillary action at a certain rate. Transdermal patches are now widely used as cosmetic, topical and transdermal delivery systems. These patches represent a key outcome from the growth in skin science, technology and expertise developed through trial and error, clinical observation and evidence-based studies that date back to the first existing human records. A transdermal patch is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through skin and into the bloodstream. An advantage of a transdermal drug delivery route over other types of delivery system such as oral, topical, intravenous (i.v.), intramuscular (i.m.), etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. The main disadvantage to transdermal delivery systems stems from the fact that the skin composition offers very effective barrier that allow only small molecule based drugs to penetrate the skin and pass through the barrier. Sildenafil citrate (SLD) is a selective cyclic guanosine monophosphate-specific phosphodiesterase type 5 inhibitor used for the oral treatment of erectile dysfunction and more recently, it has been used for the treatment of pulmonary arterial hypertension and the enhancement of uteroplacental perfusion in case of fetal growth retardation. The challenges facing the oral administration of the drug include poor bioavailability and short duration of action that requires frequent administration. The main objective of transdermal drug delivery system is to deliver drugs into systemic circulation through skin at predetermined rate with minimal inter and intrapatient variations. Keyword: Skin delivery, Transdermal drug delivery, Oral rout, Sildenafil citrate, Pulmonary arterial hypertension
APA, Harvard, Vancouver, ISO, and other styles
3

Alam, Aftab, Manjunath U. Machale, Rajkumar Prasad Yadav, Mukesh Sharma, and Akshay Kumar Patel. "Role of Transdermal Drug Delivery System." Asian Journal of Pharmaceutical Research and Development 9, no. 3 (June 15, 2021): 137–43. http://dx.doi.org/10.22270/ajprd.v9i3.976.

Full text
Abstract:
For several decades, many drug types, including tablets, capsules, pills, creams, ointments, liquids, injectables, have been used for the treatment of disease. These dosage forms must be taken multiple times a day to maintain the concentration of the medication. Transdermal drug delivery systems (TDDS), also known as “patches,” are dosage forms Built to deliver a therapeutically efficient quantity of medicine through the skin of a patient. By increasing patient compliance and preventing first pass metabolism, transdermal delivery offers a leading edge over injectables and oral routes. Transdermal drug delivery provides the patient with controlled release of the drug, allowing for a stable blood level profile, leading to decreased systemic side effects and often increased effectiveness over other types of dosage. The primary objective of the transdermal drug delivery system is to deliver drugs with minimal inter-and intrapatient variations into systemic circulation via the skin at a fixed rate.To address the difficulties of drug distribution, primarily oral routes, the transdermal drug delivery system was implemented. Modifications of the materials used were mainly limited to refinements. The present review paper discusses the overall research on the transdermal drug delivery system (TDDS) leading to the current drug delivery system (NDDS). We used convectional dosage method earlier, but we are now using a novel system of drug delivery. The transdermal patch is one of the biggest advances in the delivery of new medicines. The value of the transdermal drug delivery system is that it is a painless drug administration procedure. There are variables that influence the bioavailability of transdermal products. Such as physiochemical and biological factors. Iontophoresis, phonophoresis, electroporation and micro needles, etc, are many new techniques that have drawn interest due to technological development.
APA, Harvard, Vancouver, ISO, and other styles
4

Mali, Audumbar Digambar, Ritesh Bathe, and Manojkumar Patil. "An updated review on transdermal drug delivery systems." International Journal of Advances in Scientific Research 1, no. 6 (July 30, 2015): 244. http://dx.doi.org/10.7439/ijasr.v1i6.2243.

Full text
Abstract:
Transdermal drug delivery systems (TDDS), also known as patches, are dosage forms designed to deliver a therapeutically effective amount of drug across a patients skin. In order to deliver therapeutic agents through the human skin for systemic effects, the comprehensive morphological, biophysical and physicochemical properties of the skin are to be considered. Transdermal delivery provides a leading edge over injectables and oral routes by increasing patient compliance and avoiding first pass metabolism respectively. Transdermal delivery not only provides controlled, constant administration of the drug, but also allows continuous input of drugs with short biological half-lives and eliminates pulsed entry into systemic circulation, which often causes undesirable side effects. The TDDS review articles provide valuable information regarding the transdermal drug delivery systems and its evaluation process details as a ready reference for the research scientist who is involved in TDDS. With the advancement in technology Pharma industries have trendified all its resources. Earlier we use convectional dosage form but now we use novel drug delivery system. One of greatest innovation of novel drug delivery is transdermal patch. The advantage of transdermal drug delivery system is that it is painless technique of administration of drugs.
APA, Harvard, Vancouver, ISO, and other styles
5

Patel, Gayatri, Kantilal Narkhede, Anuradha Prajapati, and Sachin Narkhede. "A Comprehensive Review Article on Transdermal Patch." International Journal of Pharmaceutical Sciences and Medicine 8, no. 3 (March 30, 2023): 77–81. http://dx.doi.org/10.47760/ijpsm.2023.v08i03.006.

Full text
Abstract:
Transdermal drug delivery system (TDDS) established itself as an integral part of novel drug delivery systems. In a broad sense, the term transdermal delivery system includes all topically administered drug formulations intended to deliver the active ingredient into the general circulation. Transdermal drug delivery systems are polymeric formulations which when applied to skin deliver the drug at a predetermined rate across dermis to achieve systemic effects. A transdermal patch is medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. The main disadvantage to transdermal delivery systems stems from the fact that the skin is a very effective barrier; as a result, only medications whose molecules are small enough to penetrate the skin can be delivered in this method.
APA, Harvard, Vancouver, ISO, and other styles
6

Dubey, Rupal, and Umadoss Pothuvan. "Transdermal patches: an emerging mode of drug delivery system in pulmonary arterial hypertension." Journal of Drug Delivery and Therapeutics 11, no. 4-S (August 15, 2021): 176–86. http://dx.doi.org/10.22270/jddt.v11i4-s.4925.

Full text
Abstract:
Transdermal Patches have been contributing important part to the pharmaceutical industry and medical practice by providing advances in delivery of treatment with existing and novel drugs. Transdermal drug delivery system has made great contribution in the medical practices but many researches are undergoing to achieve its full potential. Transdermal drug delivery system was came into existence to overcome difficulties of drug delivery especially oral route. Transdermal drug delivery refers to means of delivering drugs through the surface of the skin for local or systemic treatment. The drug functions after absorption through skin into the systemic circulation via capillary action at certain rate. Transdermal patches are now widely used as topical and transdermal delivery systems. These patches are a significant result of advancements in skin science, technology, and knowledge, which have been created via trial and error, clinical observation, and evidence-based investigations dating back to the earliest human records. A transdermal patch is a medicated adhesive patch that is applied to the skin and used to deliver a precise amount of medicine into the bloodstream via the skin. A benefit of transdermal medication administration over other forms of delivery systems such as oral, topical, intravenous (i.v.), intramuscular (i.m.), and so on is that it is non-invasive. Transdermal patches provide medication to the patient in a regulated manner, either by a porous membrane covering a reservoir of medication or by body heat melting tiny layers of drug contained in the adhesive. This review article covers the basics of transdermal patches, such as the many types of patches, how they're made, and what factors influence them, among other things. Keyword: Skin Delivery, Transdermal Drug Delivery System, Transdermal Excipients, Pulmonary Arterial Hypertension, Sildenafil Citrate.
APA, Harvard, Vancouver, ISO, and other styles
7

heir, Mandeep Kaur, and Sachin Sharma. "Transdermal Drug Delivery System." Indo Global Journal of Pharmaceutical Sciences 09, no. 02 (2019): 155. http://dx.doi.org/10.35652/igjps.2019.92s53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yamahara, Hiroshi. "Transdermal Drug Delivery System." MEMBRANE 31, no. 1 (2006): 40–41. http://dx.doi.org/10.5360/membrane.31.40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Latif, Muhammad Shahid, Asif Nawaz, Muhammad Khursheed Alam Shah, and Asif Iqbal. "A Review on Transdermal Drug Delivery: Design, Evaluation and Approach towards Painless Drug Delivery System." Pharmaceutical Communications 1, no. 01 (December 31, 2022): 31–45. http://dx.doi.org/10.55627/pharma.001.001.0196.

Full text
Abstract:
Transdermal drug delivery systems were developed in order to overcome the difficulties associated with oral drug delivery. Through an adhesive patch affixed to the skin, transdermal patches deliver medications into the bloodstream. This treatment may benefit damaged areas of the body. Unlike oral, topical, intramuscular, and intravenous drug delivery methods, transdermal drug delivery enables controlled drug release into the body. Body heat is used to melt thin layers of medication embedded in the adhesive through the transdermal patch's porous membrane. As a barrier against foreign invaders, the skin serves as a protective layer. A medication with a molecular weight less than 500 Da can penetrate the stratum corneum through the outermost layer of the skin. An overview of transdermal patches is provided in this review article, including matrix patches, reservoir patches, membrane patches, micro reservoir patches, and patches that contain drugs in adhesive forms. These dosage forms have also been evaluated using various methods.
APA, Harvard, Vancouver, ISO, and other styles
10

Bajpai, Sharad, Kanchan Butola, and Vijaylaxmi Bisht. "Recent Advancement on TDDS (Transdermal Drug Delivery System)." Journal for Research in Applied Sciences and Biotechnology 1, no. 5 (December 7, 2022): 59–67. http://dx.doi.org/10.55544/jrasb.1.5.6.

Full text
Abstract:
The creation of a transdermal drug delivery system (TDDS) has been one of the most sophisticated and innovative approaches to drug delivery. The transdermal drug delivery system has attracted considerable attention because of its many potential advantages, including better patient compliance, avoidance of gastrointestinal disturbances, hepatic first-pass metabolism, and sustained delivery of drugs to provide steady plasma profiles, particularly for drugs with short half-lives, reduction in systemic side effects and enhanced therapeutic efficacy. This review article covers a brief outline of the transdermal drug delivery system; Highlight the restrictions, drawbacks, shortcomings, and Versatile benefits of delivery systems.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Transdermal Drug Delivery System"

1

Campbell, K. C. "Novel systems for transdermal drug delivery." Thesis, Queen's University Belfast, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.368758.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Park, Jung-Hwan. "Polymeric microneedles for transdermal drug delivery." Diss., Available online, Georgia Institute of Technology, 2004:, 2004. http://etd.gatech.edu/theses/available/etd-06072004-131324/unrestricted/park%5Fjung-hwan%5F200405%5Fphd.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Roxhed, Niclas. "A Fully Integrated Microneedle-based Transdermal Drug Delivery System." Doctoral thesis, Stockholm : Kungliga Tekniska högskolan, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-4484.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zaid, Alkilani Ahlam. "Polymeric microneedle systems for transdermal drug delivery." Thesis, Queen's University Belfast, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.603301.

Full text
Abstract:
Delivery across skin offers many advantages compared to oral or parenteral routes e.g. non-invasive, avoiding first-past metabolism, improved bioavailability and reduction of systemic side effects. Microneedle (MN) are minimally-invasive devices that painlessly by-pass the skin's stratum corneum, which is the principal barrier to topically-applied drugs. Polymeric MN delivery systems were designed and evaluated to transdermally deliver two model drugs, the small water soluble drug ibuprofen sodium and the large protein ovalbumin (OVA). A range of hydrogel forming materials for MN production was evaluated to identify the most suitable super swelling hydrogel MN array that are hard in the dry state but, upon insertion into skin, rapidly take up interstitial fluid. The MN themselves contain no drug, but instead drug are loaded into lyophilized patches. Novel super swelling hydrogel forming MN arrays were fabricated from aqueous blends containing 20% w/w poly(methyl vinyl ether co maleic acid) (Gantrez® S97), 7.5% w/w poly(ethylene glycol) (PEG) and 3% sodium carbonate (Na2C03). In addition, dissolving MN arrays loaded with a high dose of non-potent therapeutic drug were fabricated from aqueous blends of 70% w/w Gantrez® AN139 (PH 7) and 30% ibuprofen sodium. Successful drug delivery was achieved in this research work using novel polymeric MN, super swelling hydrogel MN and dissolving MN. The in vitro studies has been shown first ever example of polymeric MN being loaded with a NSAIDs. The novel concept of super swelling hydrogel MN integrated with lyophilized patches loaded with ovalbumin was evaluated. They enabled the sustained delivery of the ibuprofen sodium and ovalbumin both in vitro and in vivo. Gamma sterilization can be done without compromising polymeric MN properties. Finally, hydrogel forming MN arrays can be successfully and reproducibly applied by human volunteers given appropriate instruction so the use of MN applicator devices may not be necessary, thus possibly enhancing patient compliance.
APA, Harvard, Vancouver, ISO, and other styles
5

Kim, Yeu Chun. "Transdermal Drug Delivery Enhanced by Magainin Peptide." Diss., Georgia Institute of Technology, 2007. http://hdl.handle.net/1853/19738.

Full text
Abstract:
The world-wide transdermal drug delivery market is quite large, but only a small number of agents have FDA approval. The primary reason for such limited development is the difficulty in permeating the stratum corneum layer of human skin. In our study, we developed a novel percutaneous delivery enhancing approach. Magainin peptide was previously shown to disrupt vesicles from stratum corneum lipid components and this ability of magainin allows us to propose that magainin can increase skin permeability. Therefore, we tested the hypothesis that magainin, a pore-forming peptide, can increase skin permeability by disrupting stratum corneum lipid structure and that magainin¡¯s enhancement requires co-administration of a surfactant chemical enhancer to increase magainin penetration into the skin. In support of these hypotheses, synergistic enhancement of transdermal permeation can be observed with magainin peptide in combination of N-lauroyl sarcosine (NLS) in 50% ethanol-PBS solution. The exposure to NLS in 50% ethanol solution increased in vitro skin permeability to fluorescein 15 fold and the addition of magainin synergistically increased skin permeability 47 fold. In contrast, skin permeability was unaffected by exposure to magainin without co-enhancement by NLS-ethanol. To elucidate the mechanism of this synergistic effect, several characterization methods such as differential scanning calorimetry, Fourier transform infrared spectroscopy, and X-ray diffraction were applied. These analyses showed that NLS-ethanol disrupted stratum corneum lipid structure and that the combination of magainin and NLS-ethanol disrupted stratum corneum lipids even further. Furthermore, confocal microscopy showed that magainin in the presence of NLS-ethanol penetrated deeply and extensively into stratum corneum, whereas magainin alone penetrated poorly into the skin. Together, these data suggest that NLS-ethanol increased magainin penetration into stratum corneum, which further increased stratum corneum lipid disruption and skin permeability. Finally, skin permeability was enhanced by changing the charge of magainin peptide via pH change. We modulated pH from 5 to 11 to change the magainin charge from positive to neutral, which decreased skin permeability to a negatively charged fluorescein and increased skin permeability to a positively charged granisetron. This suggests that an attractive interaction between the drug and magainin peptide improves transdermal flux.
APA, Harvard, Vancouver, ISO, and other styles
6

Easley, Christina A. "Electrically-assisted enhancement of transdermal drug delivery using magainin peptides." Thesis, Georgia Institute of Technology, 2002. http://hdl.handle.net/1853/21419.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Zeng, Jianming. "Constrained crystallization and depletion in the polymer medium for transdermal drug delivery system." Diss., Georgia Institute of Technology, 2004. http://hdl.handle.net/1853/5102.

Full text
Abstract:
Transdermal drug delivery systems (TDS) are pharmaceutical devices that are designed to deliver specific drugs to the human body by diffusion through skin. The TDS effectiveness suffers from crystallization in the patch when they are kept in storage for more than two years. It has been reported that there are two types of crystals in the patch: needle and aggregate, and growth of drug crystals in TDS generally occurs only in the middle third of the polymer layer. In our study, fluorescence microscopy, EDS (SEM) and Raman microspectroscopy were used to further characterize the crystals. The results show that the needle crystals most probably contain estradiol and acrylic resin conjugate. The FTIR spectrum of the model sample proved the occurrence of a reaction between estradiol and acrylic resin. Crystal growth in an unstressed matrix of a dissolved crystallizable drug component was simulated using a kinetic Monte Carlo model. Simulation using Potts model with proper boundary condition gives the crystals in the middle of matrix in the higher temperature. Bond fluctuation model is also being implemented to study representative dense TDS polymer matrix. This model can account for the size effect of polymer chain on the crystal growth. The drug release profile from TDS was also studied by simulating the diffusion of drug molecules using Monte Carlo techniques for different initial TDS microstructure. The release rate and profile of TDS depend on the dissolution process of the crystal. At low storage temperature, the grains are evenly distributed throughout the thickness of the TDS patch, thus the release rate and profile is similar to the randomly initiated system. Further work on stress induced crystallization is currently under development. Although the study was specifically done for drug in a polymer medium, the techniques developed in this investigation is in general applicable to any constrained crystallization in a polymer medium.
APA, Harvard, Vancouver, ISO, and other styles
8

Narayanaswamy, Variankaval. "Characterization of phase transitions in transdermal drug delivery systems." Thesis, Georgia Institute of Technology, 1997. http://hdl.handle.net/1853/8645.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chik, Zamri. "Pharmacokinetic studies for the development of transdermal drug delivery systems." Thesis, Queen Mary, University of London, 2007. http://qmro.qmul.ac.uk/xmlui/handle/123456789/1766.

Full text
Abstract:
This thesis mainly describes a series of Phase I pharmacokinetic studies conducted on the TDS®d elivery systemw hich combinedw ith lidocaine,t estosteronea, nd a new drug, Melanotan-I for the transdermal drug delivery. Pharmacodynamic studies have also been carried out in certain areas to support the pharmacokinetics. The initial challenge was the development and validation of a method to analyse lidocaine in human plasma by LCMS-MS. The sensitivity and reliability of the developed method has enabled the analysis of lidocaine plasma levels from the TDS®- Lidocaine study. The results from the study have shown that the TDS® system has been able to deliver the drug effectively through the skin. This finding had a positive impact on the future development of the TDS® system in combination with other drugs. The combination of the TDS® system with testosterone had been successfully tested in 12 healthy male subjects. TDS®-Testosterone was found to be bioequivalent to Androgel®. This result gave an insight into further development of this preparation if it is to be regarded as an alternative treatment for hypogonadism. Various methods of correcting for endogenous testosterone were performed on the data and the influence on bioequivalence was studied. Testosterone was used as a model drug and used to explore potential guidelines for the bioequivalence assessment of endogenous compounds. Finally, the TDS® system has been combined with a new, peptide derived drug, Melanotan-I (MT-I). This drug is currently under development for the cosmetic purposes and the treatment of various skin conditions related to sun allergies. A dose escalation study of TDS®-Melanotan for the protective tanning of skin was carried out and the result was presented. In addition, in vivo techniques, such as microdialysis and tape stripping, have also been explored to investigate the feasibility of measuring pharmacokinetic of a transdermal drug instead of using the conventional systemic measurements.
APA, Harvard, Vancouver, ISO, and other styles
10

Oladiran, Gbolahan S. "Development and formulation of wax-based transdermal drug delivery systems." Thesis, Aston University, 2008. http://publications.aston.ac.uk/11060/.

Full text
Abstract:
Topical and transdermal formulations are promising platforms for the delivery of drugs. A unit dose topical or transdermal drug delivery system that optimises the solubility of drugs within the vehicle provides a novel dosage form for efficacious delivery that also offers a simple manufacture technique is desirable. This study used Witepsol® H15 wax as a abase for the delivery system. One aspect of this project involved determination of the solubility of ibuprofen, flurbiprofen and naproxen in the was using microscopy, Higuchi release kinetics, HyperDSC and mathematical modelling techniques. Correlations between the results obtained via these techniques were noted with additional merits such as provision of valuable information on drug release kinetics and possible interactions between the drug and excipients. A second aspect of this project involved the incorporation of additional excipients: Tween 20 (T), Carbopol®971 (C) and menthol (M) to the wax formulation. On in vitro permeation through porcine skin, the preferred formulations were: ibuprofen (5% w/w) within Witepsol®H15 + 1% w/w T; flurbiprofen (10% w/w) within Witepsol®H15 + 1% w/w T; naproxen (5% w/w) within Witepsol®H15 + 1% w/w T + 1% C and sodium diclofenac (10% w/w) within Witepsol®H15 + 1% w/w T + 1% w/w T + 1% w/w C + 5% w/w M. Unit dose transdermal tablets containing ibuprofen and diclofenac were produced with improved flux compared to marketed products; Voltarol Emugel® demonstrated flux of 1.68x10-3 cm/h compared to 123 x 10-3 cm/h for the optimised product as detailed above; Ibugel Forte® demonstrated a permeation coefficient value of 7.65 x 10-3 cm/h compared to 8.69 x 10-3 cm/h for the optimised product as described above.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Transdermal Drug Delivery System"

1

1954-, Guy Richard H., and Hadgraft Jonathan 1950-, eds. Transdermal drug delivery. 2nd ed. New York: Marcel Dekker, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gujarathi, Nayan A., Juliana Palma Abriata, Raj Kumar Keservani, and Anil K. Sharma. Topical and Transdermal Drug Delivery Systems. New York: Apple Academic Press, 2022. http://dx.doi.org/10.1201/9781003284017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

K, Ghosh Tapash, Pfister William R, and Yum Su Il, eds. Transdermal and topical drug delivery systems. Buffalo Grove, Ill: Interpharm Press, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Donnelly, Ryan F., and Thakur Raghu Raj Singh. Novel Delivery Systems for Transdermal and Intradermal Drug Delivery. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118734506.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Donnelly, Ryan F., and Thakur Raghu Raj Singh. Novel delivery systems for transdermal and intradermal drug delivery. Chichester, United Kingdom: John Wiley and Sons, Inc., 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Topical and transdermal drug delivery: Principles and practice. Hoboken, N.J: Wiley, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ozcan, Ipek. Current status of chitosan on dermal/transdermal drug delivery systems. Hauppauge, N.Y: Nova Science, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

J, Wille John, ed. Skin delivery systems: Transdermals, dermatologicals, and cosmetic actives. Ames, Iowa: Blackwell, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Transdermal and intradermal delivery of therapeutic agents: Application of physical technologies. Boca Raton, FL: CRC Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

1942-, Bronaugh Robert L., Maibach Howard I, and Percutaneous Absorption Symposium (1983 : Washington, D.C.), eds. Percutaneous absorption: Mechanisms--methodology--drug delivery. New York: Dekker, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Transdermal Drug Delivery System"

1

Gujarathi, Nayan A., Akshada A. Bakliwal, Bhushan R. Rane, Raj Kumar Keservani, Tulshidas S. Patil, Meenendra Tripathi, and Gulam Mohammed Husain. "Pulmonary Drug Delivery System." In Topical and Transdermal Drug Delivery Systems, 205–34. New York: Apple Academic Press, 2022. http://dx.doi.org/10.1201/9781003284017-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Desai, Jagruti L., Tosha Pandya, and Ashwini Patel. "Nanocarriers in Transdermal Drug Delivery." In Nanocarriers: Drug Delivery System, 383–409. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-33-4497-6_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shah, Vinod P., and Roger L. Williams. "Transdermal Drug Delivery Systems." In Topical Drug Bioavailability, Bioequivalence, and Penetration, 319–28. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1289-6_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Garg, Anuj, and Sanjay Singh. "Transdermal Drug Delivery Systems." In In-Vitro and In-Vivo Tools in Drug Delivery Research for Optimum Clinical Outcomes, 51–78. Boca Raton : Taylor & Francis, 2018.: CRC Press, 2018. http://dx.doi.org/10.1201/b22448-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Gujarathi, Nayan A., Akshada A. Bakliwal, Bhushan R. Rane, Vasim Pathan, and Raj Kumar Keservani. "Nanoencapsulated Nasal Drug Delivery System." In Topical and Transdermal Drug Delivery Systems, 235–57. New York: Apple Academic Press, 2022. http://dx.doi.org/10.1201/9781003284017-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brown, Marc B., Matthew J. Traynor, Gary P. Martin, and Franklin K. Akomeah. "Transdermal Drug Delivery Systems: Skin Perturbation Devices." In Drug Delivery Systems, 119–39. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-210-6_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thakkar, Hetal, Kartik Pandya, and Brijesh Patel. "Microneedle-Mediated Transdermal Delivery of Tizanidine Hydrochloride." In Drug Delivery Systems, 239–58. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9798-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ramezanli, Tannaz, Krizia Karry, Zheng Zhang, Kishore Shah, and Bozena Michniak-Kohn. "Transdermal Delivery of Drugs Using Patches and Patchless Delivery Systems." In Drug Delivery, 207–26. Hoboken, NJ: John Wiley & Sons, Inc, 2016. http://dx.doi.org/10.1002/9781118833322.ch11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gupta, Rakesh, and Beena Rai. "Computer-Aided Design of Nanoparticles for Transdermal Drug Delivery." In Drug Delivery Systems, 225–37. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-9798-5_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jahangir, Mohammed Asadullah, Abdul Muheem, Chettupalli Anand, and Syed Sarim Imam. "Recent Advancements in Transdermal Drug Delivery System." In Pharmaceutical Drug Product Development and Process Optimization, 191–216. Includes bibliographical references and index.: Apple Academic Press, 2020. http://dx.doi.org/10.1201/9780367821678-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Transdermal Drug Delivery System"

1

NASTI, IVANA, VERA LA FERRARA, GABRIELLA RAMETTA, and GIROLAMO DI FRANCIA. "SILICON BASED TRANSDERMAL DRUG DELIVERY SYSTEM." In Proceedings of the 12th Italian Conference. WORLD SCIENTIFIC, 2008. http://dx.doi.org/10.1142/9789812833594_0049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Miyano, T., T. Miyachi, T. Okanishi, H. Todo, K. Sugibayashi, T. Uemura, N. Takano, and S. Konishi. "Hydrolyticmicroneedles as Transdermal Drug Delivery System." In TRANSDUCERS 2007 - 2007 International Solid-State Sensors, Actuators and Microsystems Conference. IEEE, 2007. http://dx.doi.org/10.1109/sensor.2007.4300141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Uzunovic, A., S. Pilipovic, A. Sapcanin, and Z. Ademovic. "Evaluation of transdermal drug-delivery system of capsaicin." In GA 2017 – Book of Abstracts. Georg Thieme Verlag KG, 2017. http://dx.doi.org/10.1055/s-0037-1608515.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hou, Zhenqing, Chenghong Lin, and Qiqing Zhang. "Design of a Smart Transdermal Insulin Drug Delivery System." In 2010 4th International Conference on Bioinformatics and Biomedical Engineering (iCBBE). IEEE, 2010. http://dx.doi.org/10.1109/icbbe.2010.5517141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Modelling Transdermal Drug Delivery through a Two-layered System." In Special Session on Modelling and Simulation in Biology and Medicine. SciTePress - Science and and Technology Publications, 2013. http://dx.doi.org/10.5220/0004619706450651.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dolzan, T., D. Vrtacnik, D. Resnik, U. Aljancic, M. Mozek, B. Pecar, and S. Amon. "Design of transdermal drug delivery system with PZT actuated micropump." In 2014 37th International Convention on Information and Communication Technology, Electronics and Microelectronics (MIPRO). IEEE, 2014. http://dx.doi.org/10.1109/mipro.2014.6859540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Langer, Matt, Sabrina Lewis, Shane Fleshman, and George Lewis. ""SonoBandage" a transdermal ultrasound drug delivery system for peripheral neuropathy." In ICA 2013 Montreal. ASA, 2013. http://dx.doi.org/10.1121/1.4801417.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Jingzhi. "Drug Flux Characteristics of Transdermal Drug Delivery System Based on Hollow-Microneedle Array." In 2011 International Workshop on Engineering Application Research. Hangzhou: IEIT Press, 2011. http://dx.doi.org/10.5813/www.ieit-web.org/ips.1.84.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Paik, Seung-Joon, Seong-Hyok Kim, Po-Chun Wang, Brock A. Wester, and Mark G. Allen. "Dissolvable-tipped, drug-reservoir integrated microneedle array for transdermal drug delivery." In 2010 IEEE 23rd International Conference on Micro Electro Mechanical Systems (MEMS). IEEE, 2010. http://dx.doi.org/10.1109/memsys.2010.5442502.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chen, Kai. "A Novel Piezo-Driven Micro-Jet Injection System for Transdermal Drug Delivery." In ASME 2009 4th Frontiers in Biomedical Devices Conference. ASMEDC, 2009. http://dx.doi.org/10.1115/biomed2009-83020.

Full text
Abstract:
A novel piezo-driven micro-jet injection system is presented for transdermal drug delivery. The system uses an amplified piezoelectric actuator and a precision ball screw to accumulate the displacement of each pulsed injection. The device effectively eliminates the flow restrictor in the ampoule.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Transdermal Drug Delivery System"

1

McPhillips, D. M., M. W. Price, J. W. Gibson, and R. A. Casper. Development of an On-Demand, Generic, Drug-Delivery System. Fort Belvoir, VA: Defense Technical Information Center, August 1985. http://dx.doi.org/10.21236/ada158550.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pflugfelder Ghanashyam S., Stephen C. Broadly Applicable Nanowafer Drug Delivery System for Treating Eye Injuries. Fort Belvoir, VA: Defense Technical Information Center, September 2014. http://dx.doi.org/10.21236/ada613401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dash, Alekha K. Novel in Situ Gel Drug Delivery System for Breast Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, July 2007. http://dx.doi.org/10.21236/ada474685.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Silva, João, Matheus Warmeling, and Rogério Pagnoncelli. Platelet-rich fibrin as a drug delivery system: a scoping review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2023. http://dx.doi.org/10.37766/inplasy2023.8.0004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sledge, George W. Nanoparticle: Monoclonal Antibody Conjugates: A Novel Drug Delivery System in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2002. http://dx.doi.org/10.21236/ada420569.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sledge, George. Nanoparticle: Monoclonal Antibody Conjugates: A Novel Drug Delivery System in Human Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2000. http://dx.doi.org/10.21236/ada393348.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chakraborty, Payel, and Tamilvanan Shunmugaperumal. Simvastatin repurposing towards endometriosis management: The use of self -nanoemulsifying drug delivery system. Peeref, April 2023. http://dx.doi.org/10.54985/peeref.2304p6131285.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Choi, Soojeong, Seoeun Oh, and Ildoo Chung. Synthesis and characterization of L-lysine polyurethane (LPU) nanoparticles for drug delivery system. Peeref, July 2023. http://dx.doi.org/10.54985/peeref.2307p9824908.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Choi, Soojeong, Seoeun Oh, and Ildoo Chung. Synthesis and characterization of L-threonine polyurethane (LTHU) nanoparticles for drug delivery system. Peeref, July 2023. http://dx.doi.org/10.54985/peeref.2307p3992803.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Silva, João, Matheus Warmeling, and Rogerio Pagnoncelli. Platelet-rich fibrin as a drug delivery system: Systematic review of in vitro studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2023. http://dx.doi.org/10.37766/inplasy2023.8.0005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Transdermal Drug Delivery System' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography